News

This decision was made based on a review of available Phase 2 efficacy data and in consideration of the evolving marketplace and the growing number of treatment options

The Pennsylvania-based specialty pharmaceutical company said that the phase 2 study FAB-C had met its primary endpoint by recording an improvement by 46% at week twelve in the

"Novartis pioneers new therapeutic paradigms, creating definitive medicines for life-threatening diseases," said Jay Bradner, President of the Novartis Institutes for BioMedical Research. "Our Berkeley alliance powerfully extends our

Tricida plans to report topline results from this study in the second quarter of 2018. If successful, TRCA-301 will serve as the pivotal trial for the submission of

Through the investment, Evotec which calls itself as a drug discovery alliance and development partnership company has become the first strategic shareholder in Exscientia. Evotec with over 1,800

“This alliance aims to define patients with solid tumors who may benefit from immunotherapy and to develop therapy resistance strategies,” said Aung Naing, M.D., associate professor of Investigational

The New York-based biopharmaceutical company said that the preliminary results were observed from the first six subjects enrolled in the open-label trial dubbed NCT02226146. Immune Pharmaceuticals stated that

Jacobs was selected for this project phase following the successful completion of the conceptual study and basic engineering design As Ferring Pharmaceuticals’ principal biopharmaceutical product development center, this

Bevespi Aerosphere showed a significant improvement in lung function as measured by trough forced expiratory volume in one second (FEV1), compared to its monotherapy components (glycopyrronium 14.4 µg